Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082784
Status:
COMPLETED
Last Update Posted:
2014-12-23
First Post:
2004-05-14
Brief Title:
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue |
| Nodal Marginal Zone Lymphoma |
| Recurrent Adult Diffuse Large Cell Lymphoma |
| Recurrent Adult Diffuse Mixed Cell Lymphoma |
| Recurrent Adult Diffuse Small Cleaved Cell Lymphoma |
| Recurrent Grade 1 Follicular Lymphoma |
| Recurrent Grade 2 Follicular Lymphoma |
| Recurrent Grade 3 Follicular Lymphoma |
| Recurrent Mantle Cell Lymphoma |
| Recurrent Marginal Zone Lymphoma |
| Refractory Plasma Cell Myeloma |
| Splenic Marginal Zone Lymphoma |
| Waldenstrom Macroglobulinemia |
Keywords: